The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Utility of multi-gene panel-based germline analysis following genomic profiling and cascade testing in advanced solid tumors: An initial report of the BRANCH study.
 
Takeshi Kuwata
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Celltrion; Daiichi Sankyo; MSD; Ono Pharmaceutical; Roche
Consulting or Advisory Role - Astellas Pharma; Roche
Research Funding - Daiichi Sankyo; Ono Pharmaceutical; Roche
 
Yoshiaki Nakamura
Honoraria - Chugai Pharma; Guardant Health AMEA; Merck
Research Funding - Chugai Pharma (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Naoki Takahashi
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hiroto Narimatsu
Research Funding - Chugai Pharma; Takeda
 
Hourin Cho
No Relationships to Disclose
 
Chiaki Inagaki
Stock and Other Ownership Interests - Daiichi Sankyo/UCB Japan; Eisai
Speakers' Bureau - Daiichi Sankyo/UCB Japan; MSD; Taiho Pharmaceutical
Research Funding - Astellas Pharma; Epochal Precision Anti-Cancer Therapeutics; Ono Pharmaceutical
Travel, Accommodations, Expenses - Takeda
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Merck KGaA; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yoshinaga Okugawa
No Relationships to Disclose
 
Sawako Matsuzaki
Honoraria - AstraZeneca; Chugai Pharma
 
Naohiro Tomita
Honoraria - Sysmex; Taiho Pharmaceutical
 
Hisateru Yasui
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Incyte; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Merck; MSD K.K
Research Funding - Chugai Pharma; Lilly Japan; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda
 
Manami Matsukawa
No Relationships to Disclose
 
Kaori Kimura
No Relationships to Disclose
 
Yumie Hiraoka
Honoraria - Yakult Honsha
 
Makoto Hirata
No Relationships to Disclose
 
Issei Imoto
Research Funding - Fujitsu
 
Shinji Kosugi
Research Funding - Konica Minolta
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Genomedia (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)